Anti-tumor effects of (1 → 3)-β-d-glucan from Saccharomyces cerevisiae in S180 tumor-bearing mice
- 1 February 2017
- journal article
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 95, 385-392
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (11247010, 31400711)
- Natural Science Foundation of Hebei Province (C2013202244)
This publication has 40 references indexed in Scilit:
- Solution Properties and in Vitro Anti-Tumor Activities of Polysaccharides from Longan PulpMolecules, 2013
- Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase InhibitorsJournal of Thoracic Oncology, 2013
- The BCL-2 Family ReunionMolecular Cell, 2010
- The effects of β-glucan on human immune and cancer cellsJournal of Hematology & Oncology, 2009
- Perspectives for Cancer Prevention With Natural CompoundsJournal of Clinical Oncology, 2009
- Combined yeast-derived β-glucan with anti-tumor monoclonal antibody for cancer immunotherapyExperimental and Molecular Pathology, 2009
- Yeast-Derived β-Glucan Augments the Therapeutic Efficacy Mediated by Anti–Vascular Endothelial Growth Factor Monoclonal Antibody in Human Carcinoma Xenograft ModelsClinical Cancer Research, 2008
- Apoptosis: A Review of Programmed Cell DeathToxicologic Pathology, 2007
- Immune surveillance of tumorsJournal of Clinical Investigation, 2007
- Ganoderma lucidum polysaccharides peptide inhibits the growth of vascular endothelial cell and the induction of VEGF in human lung cancer cellLife Sciences, 2006